Skip to content
request demo
Trusted by 25+ global pharmaceutical companies

The Full Indication Landscape. Continuously Updated. Ready to Distribute.

Ferma's Landscape Assessment Agentic Workflow delivers a complete picture of any therapeutic area — every competitor in the pipeline, every mechanism being evaluated, every readout scheduled, and every unmet need still uncovered — structured for your team and formatted for distribution.

request demo

What the Landscape Assessment Delivers

Target Product Profile Benchmarking
Full TA Pipeline Overview
Every asset in the indication — pre-clinical through approved — with mechanism, phase, trial IDs, efficacy data, regulatory status, and expected catalysts. Scored and ranked.
Com Lands
Competitive Positioning Analysis
Head-to-head comparison of key assets on efficacy, safety, dosing, and commercial positioning. Structured for CI reporting and medical team briefings.
Unmet Needs
Unmet Need Identification
Maps where the current evidence base leaves unmet clinical need — by patient population, endpoint, and mechanism — using trial data, conference presentations, and publication analysis.
market dynamics
Market Dynamics Summary
Market size, patient population, key payer dynamics, pricing benchmarks, and market share trends — contextualized against the competitive pipeline.
catalyst
Readout & Catalyst Calendar
All upcoming Phase II/III readouts, PDUFA dates, conference presentations, and FDA actions in the TA — organized by timeline and competitive relevance.

Who uses it

01

Competetive Intelligence

Track how the evidence base in your TA is evolving and where competitors are building clinical differentiation.

02

New Product Planning

Map evidence gaps that inform TPP development — identifying the clinical differentiation attributes that matter most to prescribers and payers.

03

Medical Affairs

Understand the full evidence landscape your MSLs and KOLs navigate — and where your asset's evidence package stands relative to competitors.

quote

Our indication landscape used to be a quarterly deliverable that was outdated by the time it was distributed. With Ferma it's live — I can pull it the morning of a leadership meeting.

VP, Therapeutic Area Strategy
Global Biopharma
CTA Home

Build your strategy on a landscape that updates when the market does.

Request Demo

Frequently Asked Questions

How is Ferma's Landscape Assessment different from a Cortellis TA report?

Cortellis TA reports are periodic exports — updated quarterly at best, requiring manual interpretation and formatting. Ferma's Landscape Assessment Agentic Workflow monitors the indication continuously and produces a finished, structured brief on demand — updated with the latest readouts, filings, and conference presentations. Cortellis data refreshes approximately 60% annually; Ferma monitors daily.

How often does the landscape update?

Ferma monitors your configured indication continuously — updating automatically as new trial data is registered, conference presentations are indexed, regulatory actions are filed, or earnings calls are published. You can receive scheduled email briefs or access the live dashboard at any time.

Can the Landscape Assessment cover China pipeline?

Yes. Ferma monitors Chinese trial registries and NMPA filings in native language, providing coverage of early-stage assets that western-centric platforms consistently miss. China pipeline coverage is particularly relevant for indications where Chinese biotechs are active — oncology, metabolic disease, and immunology in particular.